Embecta faces July 10 securities fraud class action over insulin pens

Embecta Corp. was hit with a securities fraud class action on July 10 after insulin pen defects caused its stock to drop, Bleichmar Fonti & Auld LLP said.

The lawsuit, announced by Bleichmar Fonti & Auld, alleges Embecta and certain senior executives violated federal securities laws by concealing product quality issues related to its insulin pen devices, according to the firm.

The class action targets the company and unnamed senior executives for making false or misleading statements about its insulin pen products, which led to a significant stock decline when the defects were revealed. The exact size of the stock drop and the dollar amount of investor losses were not disclosed in the announcement. Investors who purchased Embecta shares are eligible to join the lawsuit and may contact the firm for more information.

Bleichmar Fonti & Auld, a securities law firm that has recovered hundreds of millions of dollars for aggrieved shareholders, is investigating whether Embecta's public statements about its insulin pen products were accurate when made. Embecta, which trades on the Nasdaq under the ticker EMBC, specializes in insulin delivery devices including insulin pens and syringes.

The lawsuit exposes Embecta to potential liability and settlement costs that could pressure the stock further. The lead plaintiff deadline has not yet been set, and investors may contact the firm to learn more about their eligibility.

The class action adds legal overhang to Embecta's shares as product quality concerns already weigh on investor confidence. The next catalyst will be the lead plaintiff deadline and any subsequent court rulings on the complaint.

This article is for informational purposes only and does not constitute investment advice.